M3 stock
Price history
−31.92% over the period1 year: from ¥2,674.00 (November 17, 2025) to ¥1,820.50 (November 16, 2026), −31.92%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | ¥1,820.50 |
| October 30, 2026 | ¥1,840.50 |
| September 30, 2026 | ¥1,753.50 |
| August 31, 2026 | ¥1,834.00 |
| July 31, 2026 | ¥1,781.50 |
| June 30, 2026 | ¥1,815.00 |
| May 29, 2026 | ¥1,424.00 |
| April 30, 2026 | ¥1,504.00 |
| March 31, 2026 | ¥1,605.50 |
| February 27, 2026 | ¥1,718.00 |
| January 30, 2026 | ¥1,910.50 |
| December 30, 2025 | ¥2,114.00 |
| November 28, 2025 | ¥2,577.00 |
| November 17, 2025 | ¥2,674.00 |
At a glance
The company
Provides internet-based medical services including professional networks, recruitment platforms, clinical trials, and healthcare institution support
Latest results
Quarter to September 30, 2026 · EPS ¥16.38 (estimate ¥18.84)
Next event
TickerLandia's take on M3
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 25 vs a median of 52 over its last 10 fiscal years.
- Strong point: Financial strength (91/100 in its group). Weak point: Earnings stability (35/100).
- “Below historical valuation” (Japan): No. 6 of 20.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−33.70% from the 52-week high
Analysts · 12 analysts
Average target¥1,944.17+6.79% vs. price
Buy 5 · Hold 7 · Sell 0 · Buy
TickerLandia Fingerprint: M3
Compared with similar companies: very high financial strength.
Financials and price compared with 44 companies in related industries (health_services), worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Priceaverage58
How much it costs relative to what it produces.
Metric Value Position in group Price/book 3.00 46 EV/EBITDA 13.0 45 P/E (trailing 12 months) 26.5 54 Forward P/E 25.6 77 Price/sales 3.36 69 Profitabilityhigh72
How much it earns on revenue and capital.
Metric Value Position in group ROA 6.9% 65 Gross margin 49.5% 81 Net margin 12.8% 83 ROE 11.8% 48 Operating margin 19.5% 83 Earnings stabilitylow35
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 5.3% 10 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 59 Growthaverage59
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +2.20% 42 Average revenue growth (3 years) +15.03% 72 Revenue growth (year over year) +8.30% 63 Financial strengthvery high91
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 2.44 85 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −1.14 96 Interest coverage 70.0 99 Debt/equitycounts in reverse: lower means more financial strength 0.08 85 Dividendaverage54
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 19 years 65 Payout ratio 31.9% 50 Dividend yield 1.2% 47 Market momentumstrong68
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) +42.12% 93 1-year return −30.33% 11 Distance from 200-day average +7.23% 74 Relative strength (3 months) +27.40% 94 Riskaverage44
How much the price swings.
Metric Value Position in group Volatility (60 days) 34.0% 43 Maximum drawdown (12 months) 52.0% 79 Beta (1 year) 0.04 9
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
M3 is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2026), M3's P/E today is 25.1, below the median of its last 10 fiscal years (51.7; between 22.1 and 136.0 from 2017 to 2026). M3's Forward P/E: 25.6, −13% against the median of a group of 5 similar companies (29.4).
Compared with 5 similar companies
| Metric | M3 | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 25.6 | Middle | |
| Operating margin | 19.5% | Middle | |
| ROE | 11.8% | Middle | |
| Debt/equity | 0.08 | Middle | |
| Price/book | 3.00 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: M3. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥91.75B
Latest quarter · Q3 2026
Net income
¥10.92B
Latest quarter · Q3 2026
Quarterly net margin
11.9%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- ¥1.22T
- P/E
- 26.5
- EPS
- ¥69.01
- Volume
- 1.74M
- Daily trading
- €35.5M
- Dividend yield
- 1.21%
- Last ex-dividend on March 30, 2026
How M3 is changing
All resultsRevenue grew 15.7% a year on average over the last 5 years
Operating margin fell from 30.5% to 20.1%
Profits turn into cash: free cash flow equal to 119% of net income
Returns
M3 returns with dividends
¥1,000 invested in M3 5 years ago, on November 16, 2021, would be worth ¥291 today with dividends reinvested: −70.89% in total, −21.88% per year. On price alone it would be ¥278 (−72.17%).
| Period | M3 | Nikkei 225 | ¥1,000 becomes |
|---|---|---|---|
| 1 month | −4.74% | −6.39% | ¥953 |
| 6 months | +34.35% | −0.42% | ¥1,344 |
| Year to date | −13.88% | +21.48% | ¥861 |
| 1 year | −30.97% | +21.52% | ¥690 |
| 3 years | −23.32% | +82.95% | ¥767 |
| 5 years | −70.89% | +105.15% | ¥291 |
| 10 years | +32.20% | +242.35% | ¥1,322 |
Over the last 6 months it has done better than 74% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. Nikkei 225: price only. Calculate your investment
The chart in detail
M3: technical analysis
M3 shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 82.8% below its all-time closing high (¥10,565.00, January 25, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 47
- Between 30 and 70
- vs 200-session average
- +6.63%
Support and resistance
Price areas where M3 has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance¥2,166.75+19.02%2 touches, last on January 13, 2026
- Resistance¥1,966.00+7.99%3 touches, last on October 23, 2026
- Resistance¥1,863.50+2.36%2 touches, last on September 1, 2026
- Last price¥1,820.50
- Support¥1,724.00−5.30%4 touches, last on October 2, 2026
- Support¥1,670.00−8.27%2 touches, last on August 25, 2026
- Support¥1,604.83−11.85%3 touches, last on September 10, 2026
Volatility and risk
Over the last year it has moved little with the Nikkei 225.
- Beta (1 year) vs Nikkei 225
- 0.05
- Volatility (60 sessions, annualised)
- 33.8%
- Largest fall in the last year
- −50.88%
Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
M3: seasonality
Average monthly price change over 23 years
Over the last 23 years, the strongest month for M3 has been July: +3.90% on average, positive in 13 years out of 22. The weakest has been December: −2.21% on average, positive in 5 years out of 22. November, the current month, has been positive in 11 years out of 22 (+3.89% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +3.36% | +4.51% | 15 of 22 |
| February | +0.48% | −1.63% | 9 of 22 |
| March | +2.73% | −0.04% | 11 of 22 |
| April | +3.50% | +3.70% | 15 of 22 |
| May | +0.83% | +3.11% | 12 of 22 |
| June | +3.73% | +1.95% | 16 of 22 |
| July | +3.90% | +3.64% | 13 of 22 |
| August | −0.06% | −1.36% | 10 of 22 |
| September | +0.99% | +3.22% | 12 of 22 |
| October | +1.33% | −0.41% | 11 of 23 |
| November | +3.89% | +0.22% | 11 of 22 |
| December | −2.21% | −2.78% | 5 of 22 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
M3 and its competitors
Physicians and other healthcare professionals in Japan, the United States and the United Kingdom form the core audience of M3, Inc., which reaches them over the internet. Its members-only platform m3.com offers information, tools and services, alongside MR-kun, which delivers current medical information for daily practice, and the job sites m3.com CAREER and Yakucari for physicians and pharmacists. The company also runs online lectures, clinical trial and research services, survey panels, and the public question service AskDoctors, where registered doctors answer health questions.
- Headquarters
- Tokyo, Japan
- Employees
- 17,010
- Founded
- 2000
- Chief executive
- Itaru Tanimura
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| M32413 | $7.61B | 19.5% | 26.5 | +34.35% |
| Pro MedicusPME | $14.57B | 74.9% | 81.4 | +65.15% |
| XtalPi Holdings2228 | $3B | -124.6% | — | −32.46% |
| 4DMedical4DX | $940.03M | -813.7% | — | −47.48% |
| DoximityDOCS | $5.95B | 27.1% | 46.3 | +42.54% |
| Tempus AITEM | $13.06B | -18.5% | — | +55.99% |
Same industry or related industries, similar size. Compare M3 with its competitors · Full profile
